For many years, concerns about IT security have focused almost exclusively on digital environments: websites, e-commerce platforms, cloud databases, etc. However, the modern retail ecosystem also includes a physical component that is becoming increasingly digitized. In physical stores, devices like payment terminals (POS devices) and Wi-Fi networks play a key role in both the customer experience and operational efficiency. But just like in the online world, these systems can also become targets for cybercriminals and their attacks.

Over the past decade, scientific and technological research environments have become prime targets for advanced threat actors. Connected laboratories, with large volumes of sensitive data, critical infrastructure, and IoT devices, represent an attractive target for Advanced Persistent Threats (APTs).

The digitalization of the retail sector has been key to improving customer experience and optimizing operational processes. However, this transformation has also exposed companies in the sector to a growing wave of cyberattacks. From e-commerce platforms to point-of-sale (POS) terminals, attack surfaces have multiplied, along with the risks to data integrity and business continuity.

One of the biggest challenges in addressing cybersecurity is estimating the true cost of an attack. It’s not just about direct losses like service interruptions or financial fraud, but also secondary costs such as regulatory fines, legal fees, reputational damage, and customer churn.

The biotech sector is one of the most innovative and fastest-growing industries in recent years. By working with genetic data, developing drugs, and researching new therapies, they are a prime target for cybercriminals.

According to an IBM report, the average cost of a data breach in the manufacturing industry (including food) exceeds $4.5 million. With a highly interconnected supply chain, automated production systems, and increasing digitalization, this sector is becoming more vulnerable to cyberattacks.

In recent years, phishing has undergone a significant transformation due to the integration of artificial intelligence (AI) into cybercriminals' tactics. This evolution has led to more sophisticated and harder-to-detect attacks, increasing their prevalence and effectiveness.

The biotech sector is revolutionizing health, agriculture, and science with innovations that can change the world. But with great advancements come great risks, especially when it comes to cybersecurity. Critical information from clinical trials, intellectual property, and sensitive patient data has become the perfect target for cybercriminals and their cyberattacks.

Virtual private networks (VPNs) have been the go-to solution for ensuring secure connections to corporate networks for years. However, with the rise of remote work, the adoption of multi-cloud environments, and the increase in cyber threats, companies are rethinking their access security strategies. In this context, two new technologies are gaining popularity: SASE (Secure Access Service Edge) and ZTNA (Zero Trust Network Access).

The biotechnology sector has been one of the fastest-growing industries in recent years, known for its innovation in drug development, diagnostics, and advanced therapies. However, this progress has also attracted the attention of cybercriminals. In 2023, ransomware became one of the main threats to biotechs, jeopardizing the security of critical data and operational continuity.

The food industry is undergoing a digital transformation, adopting technologies like IoT, SCADA systems, and cloud platforms to optimize its processes. However, this evolution has also increased its exposure to cyber threats that could compromise food safety, operational continuity, and business reputation.

In the fast-paced world of biotechnology, where innovation advances at a rapid pace, information security has become an unavoidable priority. Biotech companies handle extremely sensitive data: from pioneering research to genetic information of patients. Protecting these assets is not just a matter of regulatory compliance but a necessity to ensure business continuity and stakeholder trust.